Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor

Cetuximab, an epidermal growth factor receptor inhibitor (EGFRI), was used to treat a 43-year-old female with metastatic colorectal carcinoma. While the patient initially responded well to the treatment, she developed several cutaneous side effects, including a papulopustular rash, xerosis, eczema, trichomegaly, and paronychia. These side effects were managed with oral antibiotics, topical steroids, and moisturizing emollients without discontinuing the EGFRI therapy. However, due to disease progression and the development of lung metastases, cetuximab therapy was eventually discontinued, leading to the resolution of the skin manifestations. The study highlighted the need for multidisciplinary collaboration to manage EGFRI-associated skin toxicities effectively.